Clinical Trial Update: Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating ribociclib for HR-positive, HER2-negative metastatic breast cancer is currently recruiting, sponsored by Nagoya City Unive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ribociclib (ribociclib)

Snippet

Sponsor: Nagoya City University | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING